Provincial Key Laboratory of Protein Engineering in Animal Vaccines, Research Center of Reverse Vaccinology (RCRV), Hunan Agricultural University, Changsha, Hunan, China.
Laboratory of Functional Proteomics (LFP), College of Veterinary Medicine, Hunan Agricultural University, Changsha, Hunan, China.
Expert Rev Vaccines. 2020 Mar;19(3):235-246. doi: 10.1080/14760584.2020.1738227. Epub 2020 Mar 17.
: Over the past two decades, virus-like particles (VLPs) have been developed as a new generation of vaccines against viral infections. Based on VLPs, chimeric VLPs (chi-VLPs) have been generated through genetic modifications or chemical couplings. For construction of multivalent chi-VLPs vaccines, multiple genetic engineering strategies are continuously being developed. Thus, it is important to provide a summary as reference for researchers in this field.: The representative studies on the genetic engineered multivalent chi-VLPs are summarized and mainly focused on chimeric capsid VLPs and chimeric enveloped VLPs. The advantages and limitations of each strategy are also discussed at last, as well as opinions on platform choice and future directions of eVLPs vaccines.: The design of multivalent chi-VLPs vaccines needs to meet the following specifications: 1) the incorporated antigens are suggested to display on the exposed surface of chi-VLPs and do not have excessive adverse effects on the stability of chi-VLPs; 2) the chi-VLPs should elicit protective antibodies against the incorporated antigen as well as the source virus of VLPs. However, there is no requirement of retaining the antigenicity of VLPs when using VLPs solely as carriers for antigens display or drug delivery.
: 在过去的二十年中,病毒样颗粒(VLPs)已被开发为新一代针对病毒感染的疫苗。基于 VLPs,通过遗传修饰或化学偶联已经产生了嵌合 VLPs(chi-VLPs)。为了构建多价 chi-VLPs 疫苗,多种基因工程策略正在不断发展。因此,为该领域的研究人员提供一个综述作为参考是很重要的。: 对基因工程多价 chi-VLPs 的代表性研究进行了总结,主要集中在嵌合衣壳 VLPs 和嵌合包膜 VLPs 上。最后还讨论了每种策略的优缺点,以及对平台选择和 eVLPs 疫苗未来方向的看法。: 多价 chi-VLPs 疫苗的设计需要满足以下规格:1)所包含的抗原建议展示在 chi-VLPs 的暴露表面上,并且对 chi-VLPs 的稳定性没有过多的不利影响;2)chi-VLPs 应该针对所包含的抗原以及 VLPs 的来源病毒诱导保护性抗体。然而,当仅将 VLPs 用作抗原展示或药物递送的载体时,并不需要保留 VLPs 的抗原性。